Febrile Neutropenia — Part 3: Antimicrobial Prophylaxis, G-CSF & Special Situations
Fluoroquinolone prophylaxis, antifungal prophylaxis, antiviral and PJP prophylaxis, G-CSF primary and secondary prophylaxis with dosing and timing, therapeutic G-CSF in established febrile neutropenia, and management of persistent fever and documented infections.
7. Antimicrobial Prophylaxis in High-Risk Patients
Antimicrobial prophylaxis aims to prevent infection during the period of neutropenia. The decision to use prophylaxis is based on the expected depth and duration of neutropenia, the type of malignancy, and the chemotherapy regimen.1 2 3
7.1 Antibacterial Prophylaxis — Fluoroquinolones
Indications
Fluoroquinolone prophylaxis is recommended for patients at high risk for febrile neutropenia, defined as those expected to have:1 2
- Profound neutropenia (ANC < 100 cells/μL) anticipated to last > 7 days
- This typically includes:
- Acute leukemia patients undergoing induction or consolidation chemotherapy
- Allogeneic hematopoietic stem cell transplant (HSCT) recipients during the pre-engraftment period
- Autologous HSCT recipients during the pre-engraftment period (some guidelines)
- Selected high-dose chemotherapy regimens for lymphoma
Fluoroquinolone prophylaxis is not routinely recommended for patients receiving standard-dose chemotherapy for solid tumors, even if FN risk is > 20%, as the duration of neutropenia is typically < 7 days.2
Recommended Agents
| Agent | Dose | Schedule | Notes |
|---|---|---|---|
| Levofloxacin | 500 mg PO | Once daily | Preferred by many experts due to enhanced gram-positive coverage (including viridans group streptococci) compared to ciprofloxacin |
| Ciprofloxacin | 500 mg PO | Every 12 hours | Strong gram-negative coverage including Pseudomonas; weaker gram-positive coverage |
Timing
- Start: At the onset of neutropenia (ANC < 500 cells/μL) or when neutropenia is anticipated within 1–2 days, typically starting the day after the last day of chemotherapy or per institutional protocol.
- Stop: When ANC recovers to ≥ 500 cells/μL, or when empiric antibiotic therapy for FN is initiated (do not continue prophylaxis concurrently with empiric therapy).
Concerns and Controversies
| Concern | Discussion |
|---|---|
| Fluoroquinolone resistance | Widespread prophylactic use has contributed to rising fluoroquinolone resistance among gram-negative organisms, particularly E. coli and Klebsiella species; institutional antibiograms should be monitored |
| Selection of resistant organisms | Prophylaxis may select for ESBL-producing Enterobacterales, fluoroquinolone-resistant Pseudomonas, and Clostridioides difficile |
| Altered fever presentation | Prophylaxis may mask early signs of infection, delay presentation, or lead to breakthrough bacteremia with resistant organisms that are more difficult to treat |
| Impact on empiric therapy | Patients who develop FN while on fluoroquinolone prophylaxis should not receive a fluoroquinolone-containing empiric or oral outpatient regimen; the standard oral outpatient regimen (ciprofloxacin + amoxicillin-clavulanate) is not appropriate |
| Net clinical benefit | Meta-analyses have demonstrated reduced rates of febrile episodes, documented infections, and bacteremia with fluoroquinolone prophylaxis in high-risk patients; a mortality benefit has been demonstrated in some but not all studies |
7.2 Antifungal Prophylaxis
Antifungal prophylaxis is recommended for patients at high risk for invasive fungal infections (IFI), particularly those with expected prolonged and profound neutropenia.1 2 4
Risk Stratification for Antifungal Prophylaxis
| Risk Level | Patient Population | Predominant Fungal Risk |
|---|---|---|
| High risk | Acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS) undergoing intensive induction chemotherapy; allogeneic HSCT recipients (pre-engraftment and during GVHD treatment) | Invasive aspergillosis, invasive candidiasis |
| Intermediate risk | Acute lymphoblastic leukemia (ALL) on intensive regimens; autologous HSCT recipients; patients receiving alemtuzumab or prolonged corticosteroids (≥ 20 mg prednisone equivalent daily for ≥ 2 weeks) | Primarily invasive candidiasis; aspergillosis risk variable |
| Low risk | Standard-dose chemotherapy for solid tumors; neutropenia expected < 7 days | Prophylaxis generally not indicated |
Recommended Antifungal Prophylaxis Agents
| Agent | Dose | Route | Indication | Key Notes |
|---|---|---|---|---|
| Posaconazole | 300 mg PO twice daily on day 1 (loading), then 300 mg PO once daily | Oral (delayed-release tablets preferred over oral suspension) | Preferred agent for AML/MDS induction and allogeneic HSCT with GVHD — provides coverage against both Aspergillus and Candida species | Superior to fluconazole and itraconazole in reducing invasive aspergillosis and improving survival in AML/MDS (Cornely et al., NEJM 2007)5; check for drug-drug interactions (CYP3A4 inhibitor); monitor LFTs; delayed-release tablet formulation has significantly better bioavailability than suspension |
| Posaconazole IV | 300 mg IV twice on day 1, then 300 mg IV once daily | Intravenous | Patients unable to tolerate oral posaconazole | Transition to oral formulation as soon as feasible |
| Fluconazole | 400 mg PO or IV once daily | Oral or IV | Patients at risk primarily for invasive candidiasis (e.g., autologous HSCT, some ALL regimens) — does not provide anti-Aspergillus coverage | Well-tolerated; low drug interaction profile compared to posaconazole; no activity against Aspergillus, C. krusei, or C. glabrata (variable) |
| Micafungin | 50 mg IV once daily | Intravenous | Alternative for patients unable to tolerate azoles; autologous or allogeneic HSCT recipients | Echinocandin class; excellent Candida coverage; some activity against Aspergillus (prophylaxis doses may be subtherapeutic for aspergillosis); no significant drug interactions |
| Voriconazole | 200 mg PO every 12 hours | Oral | Alternative to posaconazole when Aspergillus coverage is needed; some institutions use for allogeneic HSCT | Excellent Aspergillus coverage; significant drug interactions (CYP2C19, CYP3A4); requires therapeutic drug monitoring; visual disturbances common; hepatotoxicity risk; photosensitivity and risk of cutaneous squamous cell carcinoma with prolonged use |
| Itraconazole | 200 mg PO every 12 hours (oral solution on empty stomach) | Oral | Less commonly used given superior alternatives; may be considered when posaconazole and voriconazole are not available | Erratic absorption with capsule formulation; oral solution better absorbed but poorly tolerated (GI side effects); drug interactions; therapeutic drug monitoring recommended |
Duration of Antifungal Prophylaxis
- Continue throughout the period of neutropenia until ANC recovery to ≥ 500 cells/μL.
- In allogeneic HSCT recipients, continue during periods of significant immunosuppression (e.g., during GVHD treatment with high-dose corticosteroids), typically for 75–100 days post-transplant or longer if GVHD is present.
7.3 Antiviral Prophylaxis
Herpes Simplex Virus (HSV) Prophylaxis
HSV reactivation is common during periods of profound immunosuppression and can cause severe mucositis, esophagitis, or disseminated disease.1 2
| Agent | Dose | Indication | Duration |
|---|---|---|---|
| Acyclovir | 400 mg PO twice daily, or 800 mg PO twice daily (higher dose for HSCT) | HSV-seropositive patients undergoing HSCT (allogeneic or autologous) or intensive chemotherapy for acute leukemia | Throughout the period of immunosuppression; in HSCT, typically until engraftment or through day +30 (autologous) or longer (allogeneic — up to 1 year) |
| Valacyclovir | 500 mg PO once or twice daily | Alternative to acyclovir; improved oral bioavailability and less frequent dosing | Same as acyclovir |
Varicella-Zoster Virus (VZV) Prophylaxis
- VZV reactivation risk is significant in HSCT recipients and patients on prolonged immunosuppressive therapy.
- The same acyclovir/valacyclovir doses used for HSV prophylaxis also provide VZV prophylaxis.
- In allogeneic HSCT recipients, acyclovir prophylaxis is typically continued for at least 1 year post-transplant to prevent VZV reactivation.
Cytomegalovirus (CMV) Considerations
- CMV prophylaxis or pre-emptive monitoring is relevant primarily for allogeneic HSCT recipients and is beyond the scope of this FN-focused guideline.
- Letermovir (480 mg PO or IV daily; 240 mg if co-administered with cyclosporine) is used for CMV prophylaxis in CMV-seropositive allogeneic HSCT recipients through day +100 (or longer in selected patients).
7.4 Pneumocystis jirovecii Pneumonia (PJP) Prophylaxis
PJP prophylaxis is indicated for patients at elevated risk due to T-cell immunosuppression, not solely neutropenia. However, many patients at risk for FN also meet criteria for PJP prophylaxis.1 6
| Agent | Dose | Schedule | Notes |
|---|---|---|---|
| Trimethoprim-sulfamethoxazole (TMP-SMX) | 1 single-strength tablet (80/400 mg) PO daily, OR 1 double-strength tablet (160/800 mg) PO 3 times per week (Mon/Wed/Fri) | As noted | Preferred agent; also provides some antibacterial coverage; hold during intensive chemotherapy if ANC is very low and myelosuppression is a concern (TMP-SMX can exacerbate myelosuppression); resume when counts allow |
| Dapsone | 100 mg PO daily | Once daily | Second-line for TMP-SMX intolerant patients; check G6PD before starting (risk of hemolytic anemia in G6PD-deficient patients); monitor methemoglobin levels |
| Atovaquone | 1,500 mg PO daily (with food) | Once daily | Alternative for TMP-SMX and dapsone intolerant patients; must be taken with a fatty meal for adequate absorption |
| Pentamidine (aerosolized) | 300 mg via nebulizer | Once monthly | Third-line option; does not provide systemic coverage; inferior to TMP-SMX; risk of bronchospasm during administration |
Indications for PJP Prophylaxis in Oncology
- Allogeneic HSCT recipients (continue for ≥ 6 months post-transplant, longer if on immunosuppression)
- Autologous HSCT recipients (3–6 months post-transplant)
- Patients receiving ≥ 20 mg prednisone equivalent daily for ≥ 4 weeks
- ALL patients during treatment and for 2–3 months after completion
- Patients receiving temozolomide plus radiation for brain tumors
- Patients receiving alemtuzumab, fludarabine, or other T-cell–depleting agents
- Patients receiving idelalisib or other PI3K inhibitors
8. Granulocyte Colony-Stimulating Factor (G-CSF)
G-CSF accelerates neutrophil recovery and reduces the duration of neutropenia, the incidence of febrile neutropenia, and hospitalization. Two main formulations are available: filgrastim (short-acting) and pegfilgrastim (long-acting pegylated formulation).7 8
8.1 Available G-CSF Agents
| Agent | Mechanism | Half-life | Dosing | Administration |
|---|---|---|---|---|
| Filgrastim (and biosimilars: filgrastim-sndz, filgrastim-aafi) | Recombinant methionyl human G-CSF; binds G-CSF receptor on myeloid progenitors | ~3.5 hours | 5 mcg/kg/day subcutaneously (round to nearest vial size: 300 mcg or 480 mcg) | Daily subcutaneous injection until post-nadir ANC recovery to target (typically ≥ 2,000–10,000 cells/μL, or per institutional protocol) |
| Pegfilgrastim (and biosimilars: pegfilgrastim-jmdb, pegfilgrastim-cbqv, pegfilgrastim-bmez, pegfilgrastim-apgf) | PEGylated filgrastim; sustained duration of action via reduced renal clearance | 15–80 hours (neutrophil-mediated clearance) | 6 mg subcutaneously once per chemotherapy cycle | Single subcutaneous injection; administer ≥ 24 hours after chemotherapy and ≥ 14 days before the next chemotherapy cycle |
| Pegfilgrastim on-body injector | Same as pegfilgrastim; delivered via on-body device applied on the day of chemotherapy | Same as pegfilgrastim | 6 mg delivered approximately 27 hours after application | Applied to skin; automatically delivers dose the next day |
8.2 Primary Prophylaxis
Primary prophylaxis refers to G-CSF administration starting with the first cycle of chemotherapy before any FN episode has occurred.7 8
Indications for Primary Prophylaxis
| Estimated FN Risk | Recommendation |
|---|---|
| ≥ 20% with the planned chemotherapy regimen | G-CSF prophylaxis is recommended |
| 10–20% | G-CSF prophylaxis should be considered, particularly if patient-specific risk factors increase overall FN risk to ≥ 20% |
| < 10% | G-CSF prophylaxis is not routinely recommended |
Patient-Specific Risk Factors That May Increase FN Risk
When the chemotherapy regimen has an intermediate (10–20%) FN risk, the following patient-specific factors should be assessed to determine if overall risk rises to ≥ 20%:7 8
| Risk Factor | Details |
|---|---|
| Age ≥ 65 years | Independent risk factor for FN and FN-related complications |
| Advanced disease | Extensive tumor burden or advanced stage |
| Prior history of FN | Previous episode of FN with the same or similar regimen |
| No G-CSF prophylaxis planned | In the absence of prophylaxis, risk remains at baseline |
| Prior chemotherapy or radiation | Previous myelosuppressive treatment, particularly extensive prior chemotherapy or pelvic/craniospinal radiation (large bone marrow reserve compromise) |
| Pre-existing neutropenia | Bone marrow involvement by tumor, chronic neutropenia |
| Poor performance status | ECOG ≥ 2 |
| Comorbidities | Renal or hepatic dysfunction, HIV, poor nutritional status |
| Female sex | Slightly higher FN risk in some analyses |
| Open wounds or active infection | Active infection at the start of chemotherapy |
Examples of Chemotherapy Regimens by FN Risk
| FN Risk Category | Example Regimens |
|---|---|
| High risk (> 20%) | Dose-dense AC (doxorubicin/cyclophosphamide) every 2 weeks; BEACOPP (Hodgkin lymphoma); TC (docetaxel/cyclophosphamide for breast cancer); DHAP, ICE, ESHAP (lymphoma salvage); hyper-CVAD; cisplatin-based regimens for testicular cancer (BEP at full dose in some settings) |
| Intermediate risk (10–20%) | AC every 3 weeks (breast cancer); CHOP every 21 days (lymphoma); carboplatin/paclitaxel (selected settings); FOLFOX, FOLFIRI (colorectal, in some patient populations); docetaxel monotherapy |
| Low risk (< 10%) | Weekly paclitaxel; gemcitabine monotherapy; capecitabine; 5-FU/leucovorin; weekly vinorelbine |
8.3 Secondary Prophylaxis
Secondary prophylaxis refers to G-CSF use in subsequent cycles after a patient has experienced an FN episode or a dose-limiting neutropenic event in a prior cycle.7 8
| Scenario | Recommendation |
|---|---|
| Prior FN episode and maintaining dose intensity is important for cure or survival (e.g., curative-intent regimen) | G-CSF secondary prophylaxis is recommended to maintain chemotherapy dose intensity |
| Prior FN episode and dose reduction is acceptable (e.g., palliative chemotherapy) | Consider dose reduction or regimen change as alternative to G-CSF; G-CSF secondary prophylaxis is an option |
| Prolonged neutropenia (ANC < 500 for ≥ 7 days) without fever in prior cycle | Consider G-CSF prophylaxis in subsequent cycles |
8.4 Therapeutic G-CSF in Established Febrile Neutropenia
The use of G-CSF as treatment (not prophylaxis) in patients with established FN is more controversial.1 7 8
| Recommendation | Evidence |
|---|---|
| G-CSF is not routinely recommended for all patients with FN | Meta-analyses show G-CSF shortens duration of neutropenia and hospitalization by ~1–2 days but has not consistently demonstrated a mortality benefit in established FN |
| G-CSF may be considered in patients with FN who are at high risk for infection-related complications or who have clinical features predictive of poor outcome | Factors include: pneumonia, sepsis syndrome or septic shock, invasive fungal infection, prolonged profound neutropenia (ANC < 100 for > 10 days), age > 65, uncontrolled primary disease, multiorgan dysfunction |
| If therapeutic G-CSF is used | Filgrastim 5 mcg/kg/day subcutaneously until ANC recovery; pegfilgrastim is not studied or recommended for therapeutic use in established FN |
8.5 G-CSF Timing and Practical Considerations
| Parameter | Recommendation |
|---|---|
| Start of prophylactic G-CSF | 24–72 hours after completion of chemotherapy (do not administer concurrently with myelosuppressive chemotherapy or within 24 hours before chemotherapy) |
| Filgrastim duration | Continue daily until post-nadir ANC recovery to normal or near-normal range (≥ 2,000–10,000 cells/μL) OR per institutional protocol; typically 7–14 days |
| Pegfilgrastim timing | Single dose; administer ≥ 24 hours after chemotherapy and at least 14 days before the next cycle; do not administer between days −14 and 0 relative to the next chemotherapy |
| Common side effects | Bone pain (most common, 20–30%; treat with non-opioid analgesics such as loratadine 10 mg PO daily or naproxen); injection site reactions; splenic enlargement (rare; advise patients to report left upper quadrant pain) |
| Contraindications | Known hypersensitivity to filgrastim, pegfilgrastim, or E. coli–derived proteins; do not use in patients with sickle cell disease (risk of sickle cell crisis) |
| Monitoring | CBC with differential 2 times per week during filgrastim administration; with pegfilgrastim, check CBC per routine chemotherapy monitoring schedule |
9. Special Situations
9.1 Persistent Fever Despite Empiric Antibiotics
Persistent or recurrent fever after 4–7 days of appropriate broad-spectrum empiric antibiotics in a neutropenic patient requires systematic re-evaluation.1 2 3
Evaluation of Persistent Fever
| Step | Action |
|---|---|
| Reassess clinically | Repeat detailed history and physical examination; look for new or evolving signs of infection |
| Repeat cultures | Blood cultures (peripheral and through all CVC lumens); urine, sputum, wound cultures as indicated |
| CT imaging | CT chest (high-resolution) to evaluate for pulmonary infiltrates, including findings suggestive of invasive pulmonary aspergillosis (halo sign, nodules, air-crescent sign); CT abdomen/pelvis if abdominal symptoms; CT sinuses if facial/nasal symptoms |
| Serum biomarkers | Serum galactomannan (for invasive aspergillosis); serum 1,3-beta-D-glucan (pan-fungal marker); procalcitonin and CRP trending |
| Review antibiotics | Ensure dosing is appropriate, drug levels adequate (if applicable), and spectrum is appropriate for local resistance patterns |
| Consider broadening | Add vancomycin if not already included and specific indications are present; consider changing the beta-lactam backbone if concern for resistant organism |
| Empiric antifungal therapy | If fever persists ≥ 4–7 days despite broad-spectrum antibacterial therapy in patients with expected prolonged neutropenia, empiric antifungal therapy should be initiated (see Part 4) |
Non-Infectious Causes of Persistent Fever in Neutropenic Patients
| Cause | Considerations |
|---|---|
| Drug fever | Beta-lactams, vancomycin, G-CSF, and other medications can cause drug fever; temporal relationship with drug administration may provide clues |
| Tumor fever | Particularly in patients with lymphoma, renal cell carcinoma, or hepatocellular carcinoma |
| Venous thromboembolism | Cancer patients are at high risk for DVT/PE, which can cause fever |
| Transfusion-related | Febrile non-hemolytic transfusion reactions |
| Adrenal insufficiency | Especially in patients who have recently discontinued corticosteroids |
9.2 Documented Bacteremia
When blood cultures identify a specific organism, therapy should be tailored accordingly.1
Gram-Positive Bacteremia
| Organism | Preferred Treatment | Duration |
|---|---|---|
| Coagulase-negative staphylococci (e.g., S. epidermidis) | Vancomycin (if MRSA concern) or beta-lactam if susceptible; assess catheter as source | 5–7 days if catheter-related and catheter removed; 10–14 days if catheter retained |
| Staphylococcus aureus (MSSA) | Nafcillin or oxacillin 2 g IV every 4 hours; or cefazolin 2 g IV every 8 hours | Minimum 14 days from first negative blood culture; echocardiography recommended to exclude endocarditis; if endocarditis → 4–6 weeks |
| Staphylococcus aureus (MRSA) | Vancomycin 15–20 mg/kg IV every 8–12 hours (target AUC/MIC 400–600) | Same as MSSA: ≥ 14 days; echocardiography; infectious disease consultation strongly recommended |
| Viridans group streptococci | Penicillin G, ampicillin, or ceftriaxone (based on susceptibility) | 7–14 days; may cause septic shock and ARDS — monitor closely; ICU admission may be required |
| Enterococcus (vancomycin-susceptible) | Ampicillin 2 g IV every 4 hours (if susceptible) or vancomycin | 7–14 days depending on source |
| Enterococcus (VRE) | Linezolid 600 mg IV/PO every 12 hours or daptomycin 8–12 mg/kg IV daily | 7–14 days; infectious disease consultation recommended |
Gram-Negative Bacteremia
| Organism | Preferred Treatment | Duration |
|---|---|---|
| Pseudomonas aeruginosa | Anti-pseudomonal beta-lactam (cefepime, piperacillin-tazobactam, meropenem) based on susceptibility; consider dual therapy (beta-lactam + aminoglycoside or fluoroquinolone) for the first 3–5 days in bacteremia | Minimum 14 days; high mortality if inadequately treated |
| Escherichia coli, Klebsiella (susceptible) | Narrow to ceftriaxone, cefepime, or piperacillin-tazobactam based on susceptibilities | 7–14 days |
| ESBL-producing Enterobacterales | Meropenem 1 g IV every 8 hours (carbapenem is treatment of choice for serious ESBL infections) | 7–14 days |
| Carbapenem-resistant Enterobacterales (CRE) | Ceftazidime-avibactam 2.5 g IV every 8 hours; meropenem-vaborbactam 4 g IV every 8 hours; or based on susceptibility and infectious disease consultation | 7–14 days; infectious disease consultation essential |
| Stenotrophomonas maltophilia | TMP-SMX (15 mg/kg/day of the TMP component divided every 6–8 hours); alternative: levofloxacin or minocycline based on susceptibility | 14 days |
9.3 Neutropenic Enterocolitis (Typhlitis)
Neutropenic enterocolitis is a necrotizing inflammatory process of the cecum and surrounding bowel that occurs in severely neutropenic patients, most commonly during induction chemotherapy for acute leukemia.1
| Aspect | Details |
|---|---|
| Clinical presentation | Right lower quadrant pain, fever, diarrhea (may be bloody), abdominal distention, nausea/vomiting; may progress to peritonitis and perforation |
| Diagnosis | CT abdomen/pelvis showing cecal wall thickening (> 4 mm), pericecal inflammation, pneumatosis intestinalis, or free air; exclude C. difficile |
| Management | Broad-spectrum antibiotics with anaerobic coverage (e.g., piperacillin-tazobactam or meropenem); bowel rest; nasogastric decompression if ileus; surgical consultation for perforation, uncontrolled bleeding, or clinical deterioration despite medical therapy |
| Surgical intervention | Required in < 20% of cases; indications include perforation, massive hemorrhage, or progressive clinical deterioration; mortality is high in patients requiring surgery during profound neutropenia |
References
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2011;52(4):e56-e93. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology (ASCO) and Infectious Diseases Society of America (IDSA) clinical practice guideline update. J Clin Oncol. 2018;36(14):1443-1453. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. ↩︎ ↩︎
Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials. Cancer. 2002;94(12):3230-3246. ↩︎
Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359. ↩︎
Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;(10):CD005590. ↩︎
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology (ASCO) clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-3212. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
National Comprehensive Cancer Network (NCCN). Hematopoietic growth factors. NCCN Clinical Practice Guidelines in Oncology. Version 2.2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎